Answers are grounded in this paper and cite their sources.
Novel mesoporous magnesium tungstate catalyst shows 233% increased oxidation activity for cyclohexanone, indicating strong industrial potential.
Abstract A novel mesoporous magnesium tungstate (MgWO₄) catalyst with a yarn ball-like morphology using cetyltrimethylammonium bromide (CTAB) as a structure-directing agent was pioneered the design and successfully prepared via a solvothermal method in this work, and the catalytic performance was subsequently investigated in the Baeyer-Villiger (B-V) oxidation of cyclohexanone to ε-caprolactone within an O₂/benzaldehyde co-oxidation system. The physicochemical and structural properties of MgWO₄ were thoroughly characterized using a suite of analytical techniques, including X-ray diffraction (XRD), scanning electron microscopy (SEM), transmission electron microscopy (TEM), Nitrogen adsorption-desorption isotherms, X-ray photoelectron spectroscopy (XPS), Fourier-transform infrared spectroscopy (FT-IR), and Hammett indicator methods. The engineered pore structure can enhance oxygen adsorption capacity to promote the oxidation of cyclohexanone and alleviate mass transfer constraints. The Y-MgWO₄(22%) catalyst, exhibiting a 1.9-fold increase in specific surface area, a 3.1-fold larger pore volume, and moderate basicity, achieved catalytic activity approximately 233% higher than the CTAB-free MgWO₄ substrate. The catalyst maintained stable performance over more than eight reuse cycles, indicating its viability for industrial application.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: